Home

Suven Pharmaceuticals Ltd PE Ratio

Image

Suven Pharmaceuticals Ltd

NSE: SUVENPHAR

PE

99.7

Last updated on: Apr 03, 2025

Key Highlights

  • The P/E Ratio of Suven Pharmaceuticals Ltd is 99.7 as of 03 Apr 13:29 PM .
  • The P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 years.
  • The Latest Trading Price of Suven Pharmaceuticals Ltd is ₹ 1127 as of 03 Apr 13:21 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 21.0 to 40.0 in 5 years. This represents a CAGR of 13.75%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.2. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.1 in 2024.

Historical P/E Ratio of Suven Pharmaceuticals Ltd

No data available

Company Fundamentals for Suven Pharmaceuticals Ltd

Image

Suven Pharmaceuticals Ltd

NSE: SUVENPHAR

Share Price

₹ 1127.15

33.50 (3.06%)

stock direction

Last updated on: Apr 03, 2025

Market Price of Suven Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Suven Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
02 Apr 20251093.65
01 Apr 20251074.5
28 Mar 20251159.8
27 Mar 20251109.3
26 Mar 20251113.4
25 Mar 20251151.75
24 Mar 20251173.95
21 Mar 20251209.85
20 Mar 20251194.9
19 Mar 20251161.8

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

che

Weakness

1

che

Opportunity

0

che

Threats

0

che

BlinkX Score for Suven Pharmaceuticals Ltd

Asset Value vs Market Value of Suven Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in ₹ crores

Competitive Comparison of P/E Ratio

Company
leftMarket Capright
Suven Pharmaceuticals Ltd27840
Sun Pharmaceutical Industries Ltd411306
Divis Laboratories Ltd150343
Cipla Ltd117323
Torrent Pharmaceuticals Ltd108614
Mankind Pharma Ltd99891

PE Ratio of Suven Pharmaceuticals Ltd Explained

27840

Market cap

279

Earnings

99.7X

PE Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Suven Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue, EBITDA and Net Profit of Suven Pharmaceuticals Ltd

Revenue

EBITDA

Net Profit

No data available

* All values are in crore

Historical Dividend Payout of Suven Pharmaceuticals Ltd

No data available

* All values are in %

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors.
  • Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations.
  • Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.

Suven Pharmaceuticals Ltd News Hub

Suven Pharmaceuticals consolidated net profit declines 49.61% in the June 2024 quarter

Net profit of Suven Pharmaceuticals declined 49.61% to Rs 60.77 crore in the quarter ended June 2024

Read more

09 Aug 24

Suven Pharmaceuticals to hold board meeting

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 August 2024.

Read more

06 Aug 24

Suven Pharmaceuticals appoints Vivek Sharma as new Executive Chairman

Suven Pharmaceuticals announced the appointment of Vivek Sharma as the new Executive Chairman, effec

Read more

19 Sept 24

Board of Suven Pharmaceuticals approves change in Executive Chairperson

The Board of Suven Pharmaceuticals at its meeting held on 19 September 2024 has taken on record the

Read more

19 Sept 24

Product Composition by Percentage (Revenue)

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Suven Pharmaceuticals Ltd

What is the current PE Ratio of Suven Pharmaceuticals Ltd?

The Current PE Ratio of Suven Pharmaceuticals Ltd is 99.69 as on 3 Apr 2025.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 3 Apr 2025.

What was the PE Ratio of Suven Pharmaceuticals Ltd last year?

The PE Ratio of Suven Pharmaceuticals Ltd was 29.25 last year, now the PE ratio is 99.69, showing a year-on-year growth of 240.8%.

What does the PE Ratio of Suven Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Suven Pharmaceuticals Ltd is 99.69. This ratio indicates that investors are willing to pay 99.69 times the earnings per share for each share of Suven Pharmaceuticals Ltd.

What is the PE Ratio Growth of Suven Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Suven Pharmaceuticals Ltd grew by 240.8% whereas, the EPS ratio grew by 0.9.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions